Crescent Biopharma, Inc. CBIO
Set alert
12.91 USD -0.57 -4.23%
At close · Nov 2
12.91 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
12.68 Day range 13.92
8.72 52-week range 27.41
- YTD
- +8.85%
- 1 year
- +1.25%
- Open
- 13.75
- Prev close
- 13.48
- Mkt cap
- 479.57M
- Vol
- 147.31K
- Avg vol
- 347.38K
- EPS
- -7.63
- P/E
- 0.00
- Div yield
- 792.92%
More statistics
- Low
- 12.68
- High
- 13.92
- Forward P/E
- -17.04
- Beta
- 1.29
- Short ratio
- 0.19
- Inst. own
- 8.75%
- Dividend
- 15.94
- Ex-div date
- Jan 12, 2023
- Earnings
- Oct 26, 2023
- 50-d avg
- 0.638078
- 200-d avg
- 0.365086
- 1y target
- 0.00
1M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 19 hours ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
Analyst view
Consensus: hold
Hold
Price target (mean) 0.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 1
- 2 months ago 1
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.05 – -0.05 | 1.64 | -103.0% | 0 | 0.0% | 1 |
| Next quarter | -0.04 | -0.04 – -0.04 | -0.16 | +75.0% | 0 | 0.0% | 1 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | -0.03 | -0.03 – -0.03 | 0.00 | 0.0% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| Aug 5, 2021 | Raymond James | Maintained | — | Outperform |
| Apr 28, 2021 | Raymond James | Maintained | — | Outperform |
| Feb 9, 2021 | Piper Sandler | Initiated | — | Overweight |
| Feb 3, 2021 | Raymond James | Maintained | — | Outperform |
| Jan 3, 2019 | Oppenheimer | Initiated | — | Outperform |
| Jun 20, 2018 | B. Riley Securities | Downgrade | Buy | Neutral |
| Feb 11, 2018 | B. Riley Securities | Maintained | Buy | Buy |
| Feb 8, 2018 | Chardan Capital | Maintained | Buy | Buy |
| Dec 7, 2017 | B. Riley Securities | Initiated | — | Buy |
| Jun 11, 2017 | Chardan Capital | Initiated | — | Buy |
| Jun 5, 2017 | Ladenburg Thalmann | Initiated | — | Buy |
| Jun 29, 2016 | Rodman & Renshaw | Initiated | — | Buy |